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For 89 human immunodeficiency virus (HIV)–positive and 32 HIV-negative immunocom-
promised patients who had 121 episodes of Pneumocystis carinii pneumonia (PCP), clinical
features and changes over time were compared. HIV-infected patients characteristically had
a longer duration of symptoms (23 vs. 13 days; ); were younger (39 vs. 48 years;P ! .005
); had a higher frequency of sweating, weight loss, and thoracic pain; and had fewerP ! .001
admissions to the intensive care unit (16% vs. 31%; ). In addition, they had significantlyP ! .05
higher hemoglobin levels, lower thrombocyte counts, lower C-reactive protein values, and a
higher proportion of eosinophils and lymphocytes in bronchoalveolar lavage fluid. After 1995,
HIV-negative patients’ mean length of stay dropped from 34 days to 16 days ( ), andP ! .005
their hospital mortality rate dropped from 29% to 7% ( ). HIV-positive patients withP ! .001
PCP differed in several aspects from those without HIV infection. Knowledge gained from
experience with treatment of opportunistic infections in patients with AIDS has improved
the management of PCP in patients with other immunodeficiencies.
Pneumocystis carinii was first appreciated as a human path-
ogen when it was causally related to pneumonia in premature,
marasmic infants in European orphanages after World War II
[1]. From the 1950s to the 1970s, ∼100 cases of P. carinii pneu-
monia (PCP) in severely immunocompromised patients were
diagnosed and reported each year in the United States [2, 3].
Cases increased markedly with the outbreak of the HIV epi-
demic. Since then, medical interest in PCP has focused on pa-
tients with AIDS. However, with the increasing number of pa-
tients receiving organ transplants, immunosuppressive therapy
for a large variety of other diseases, and high-dose chemo-
therapy, PCP has become more frequent in such patients. PCP
now occurs in immunocompromised patients with various un-
derlying diseases [4–12].
Few studies have analyzed PCP in patients with AIDS as
compared to those with other immunodeficiencies [13–16].
These studies mainly included patients from the 1980s. There-
fore, the effect of PCP prophylaxis and, in particular, highly
active antiretroviral therapy (HAART, which has dramatically
changed the outcome of HIV infection in the 1990s) could not
be assessed. Increasing awareness of PCP, as well as diagnostic
and therapeutic progress, may have changed the picture of this
disease, especially in HIV-infected patients. The present study
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was performed to compare clinical features of PCP in patients
with and without HIV infection. Attention was given to changes
that have occurred over time.
We were confronted with an increasing number of cases of
PCP involving patients without HIV infection, whereas the
yearly incidence of PCP in HIV-infected patients remained sta-
ble after the introduction of effective prophylaxis for PCP and
even declined when HAART became available [17–21]. The
pathogenesis of PCP may be different in patients with AIDS
and those with compromised immunity due to other causes [22].
In addition, it is likely that underlying diseases, as well as the
awareness of the treating physicians, may have influenced the
course and outcome of PCP in the 2 groups. Therefore, we
analyzed data from all patients with PCP from 1983, when the
first case was diagnosed in our institution, to June 1998. HIV-
positive patients were compared to HIV-negative immunocom-
promised hosts with PCP.
Patients and Methods
The Basel University Hospital, in Basel, Switzerland, is an 800-
bed facility that has averaged 230,000 patient-days per year during
the past 5 years. It offers primary as well as tertiary care and is
the major provider of acute medical care for the population of the
city of Basel.
In patients with clinical or radiological signs of PCP, the diag-
nosis was made by means of fiberbronchoscopy and bronchoal-
veolar lavage (BAL), with use of standard techniques [23, 24].
Presumptive therapy for PCP was not administered during the ob-
servation period. From the cytological database of the Institute for
Pathology (Basel), all lavages revealing P. carinii were screened.
Available charts of all patients treated for PCP at the Department
of Internal Medicine of the University Hospitals of Basel until June
1998 were selected and analyzed. Data on underlying diseases, im-
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Figure 1. Incidence of Pneumocystis carinii pneumonia (PCP): no. of patients per year with PCP admitted to University Hospitals of Basel
and included in the study. White and black columns represent HIV-positive and HIV-negative patients, respectively.
Table 1. Predisposing factors in HIV-negative patients with Pneu-
mocystis carinii pneumonia.
Underlying disorder No. (%) of patients
Renal transplantation 19 (59)
Bone marrow transplantation (BMT) 5 (16)
Hematologic malignancy without BMT 3 (9)
Chronic lymphatic leukemia 1
Hodgkin’s disease 1
Multiple myeloma 1
Autoimmune disease 4 (13)
Sarcoidosis 2
Rheumatoid arthritis 1
Rapidly progressing glomerulonephritis 1
Idiopathic CD4 cell deficiency 1 (3)
munosuppression, clinical characteristics, laboratory values, anti-
pneumocystic treatment, PCP prophylaxis, outcome, and length of
stay were extracted. Deaths due to any cause occurring during the
hospital stay were considered in determining mortality, regardless
of whether they were related to PCP.
All data were stored in a computerized database. Quantitative
parameters were given as means (5SD) when normally distributed;
otherwise, they were given as medians (minimum–maximum).
Qualitative parameters were given as proportions (percentages).
Differences were calculated by means of Fisher’s exact test on a
table for proportions and Student’s t test or Mann-Whitney2 3 2
U test for quantitative data. Statistical analysis was performed with
the software StatView 5.0 (SAS Institute, Cary, NC).
Results
During the 16-year observation period, 132 patients fulfilled
the inclusion criteria, but records were missing for 11. There-
fore, 121 patients were included in this study: 89 HIV-infected
and 32 HIV-negative immunocompromised patients. There was
a predominance of males in both groups. Of the HIV-positive
patients, 77 (87%) were male and 12 (13%) were female; of
HIV-negative patients, 20 (63%) were male, 12 (38%) female.
The number of patients with PCP admitted per year is shown
in figure 1. It increased among HIV-positive patients until 1991
(up to 12 patients a year) and started to decrease after 1995,
when HAART became available. In the last 2.5-year period,
the incidence of PCP was equal in HIV-positive and HIV-neg-
ative patients. Among the immunocompromised hosts without
HIV infection, the first case was detected in 1988, and the
number of cases increased to 5 per year, as shown in figure 1.
During the observation period, a constant number of kidneys
( ; total, 910) were transplanted each year. The yearly53 5 10
number of bone-marrow transplantations varied from 17 in
1989 to 32 in 1998 (total, 367).
AIDS patients with PCP had a median CD4 cell count of
34/mL (range, 0–530/mL). Before diagnosis of PCP, 11 (12%)
were in stage A of the Centers for Disease Control and Pre-
vention’s classifications for HIV infection, 41 (46%) were in
stage B, and 37 (42%) were in stage C, indicating that PCP was
the first AIDS-defining event in 58% of the patients. Ten (11%)
received PCP prophylaxis, and 23 (26%) had received antire-
troviral therapy; either monotherapy ( ), a combinationn = 21
of 2 nucleoside reverse transcriptase inhibitors ( ), or an = 2
triple combination including a protease inhibitor ( ).n = 1
HIV infection had been acquired by 41 (46%) of 89 patients
through homosexual intercourse; by 27 (30%) of 89 through
illicit iv drug use; and by 12 (13%) of 89 through heterosexual
intercourse. For the remaining 9 (10%) of 89 patients, the ac-
quisition of HIV infection was of another or unknown pattern.
In all patients without HIV infection, an underlying condition
impairing the immune system or a disorder treated with im-
munosuppressive agents was present. Immunosuppression for
transplantation was the major contributing factor (table 1). The
median lapse between transplantation and diagnosis of PCP
was 125 days for kidney transplant recipients and 95 days for
bone marrow–transplant recipients. CD4 lymphocyte counts
were not routinely assessed. The median absolute lymphocyte
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Table 2. Clinical characteristics of patients with Pneumocystis carinii
pneumonia (PCP).
Clinical characteristic
HIV-positive
(n = 89)
HIV-negative
(n = 32) P
Age (y) 39 5 9.9 48 5 13 !.001a
Duration of symptomsb (d) 23 5 17 13 5 12 !.005a
Systolic blood pressure (mm Hg) 115 5 15 125 5 20 !.05a
Diastolic blood pressure (mm Hg) 71 5 11 73 5 12 .46
Tachycardia, 1100/min 24 (27) 8 (25) .99
PCP prophylaxis 10 (11) 0 (0) —
Cough 60 (67) 18 (56) .68
Dyspnea 49 (55) 20 (63) .54
Expectoration 30 (39) 8 (25) .51
Tachypnea, 115/min 30 (34) 7 (22) .64
Thoracic pain 25 (28) 3 (9) !.05c
Hemoptysis 3 (4) 3 (9) .19
Fever 1387C 56 (62) 20 (63) .99
Weakness 51 (57) 15 (47) .41
Loss of appetite 42 (47) 12 (38) .41
Sweating 39 (44) 6 (19) !.05c
Weight loss 38 (43) 4 (13) !.01c
Cachexia 32 (36) 3 (9) !.01c
NOTE. Data are no (%) of patients or .mean 5 SD
a Unpaired Student’s t test, two-tailed.
b Until diagnosis of PCP.
c Fisher’s exact test.
Table 3. Laboratory values at diagnosis of PCP for HIV-positive and
HIV-negative patients.
Parameter HIV-positive HIV-negative Pa
Arterial partial pressure of CO2 (kPa) 4.350.7 4.650.9 .13
Arterial partial pressure of O2 (kPa) 9.153.6 9.253.8 .91
Arterial pH 7.4350.07 7.4350.11 .91
Hemoglobin (g/dL) 11.652.2 9.5251.7 !.01
Leukocytes (3109/L) 5.252.1 6.454.0 .11
Thrombocytes (3109/L) 212584.8 2625148 !.05
Lactate dehydrogenase (mmol/L) 9305668 6345358 .11
C-reactive protein (mg/L) 66553.6 1235114 !.01
NOTE. Data are .mean 5 SD
a Unpaired Student’s t test, two-tailed.
count was 380/mL (range, 0–3370/mL). None of these patients
received PCP prophylaxis.
HIV-infected patients were younger than HIV-negative pa-
tients (mean age, 39 vs. 48 years; ), and the time fromP ! .001
the onset of symptoms until diagnosis of PCP was longer (23
vs. 13 days; ). Main features of PCP, such as pulmonaryP ! .005
symptoms, fever, and weakness, occurred at similar frequencies
in both groups. In contrast, significant differences were found
with regard to thoracic pain, sweating, weight loss, and ca-
chexia, all of which occurred more frequently in HIV-infected
patients (table 2).
There was no difference in the gas exchange values between
the 2 groups. In contrast, HIV-positive patients had higher
values for hemoglobin, lower thrombocyte counts, and lower
values for C-reactive protein (table 3).
Cytological analyses of BAL specimens showed 13% neu-
trophils in 51 (74%) of 69 HIV-positive patients and 18 (67%)
of 27 HIV-negative patients ( ). Eosinophils were foundP 1 .05
significantly more often in the BAL specimens from HIV-pos-
itive patients (23 [33%] of 69 vs. 2 [7%] of 27; ). Similarly,P ! .01
a finding of 115% lymphocytes was more frequent for HIV-
positive patients (41 [59%] of 69 vs. 13 [48%] of 27; ).P ! .05
The length of hospital stay was significantly shorter for HIV-
positive patients than for HIV-negative patients in the period
of 1983–1995 (table 4). It dropped 2.1-fold ( ) from theP ! .005
earlier to the later period for HIV-negative patients, whereas
it remained similar in both periods for HIV-infected patients.
For the whole observation period, the length of stay did not
differ in the 2 groups. However, a larger proportion of the HIV-
negative cohort was admitted to the intensive care unit (ICU)
and required mechanical ventilation (table 4). There was a trend
toward a higher hospital mortality rate in this group, but mor-
tality dropped 4.1-fold ( ) to reach 7% in the period ofP ! .001
1996–1998 (figure 2).
The antimicrobial agents administered to HIV-positive and
HIV-negative patients (including switches in therapy) were co-
trimoxazole (62% vs. 72%), dapsone/trimethoprim (28% vs.
25%), pentamidine (11% vs. 16%), and atovaquone (1.1% vs.
38%; ).P ! .001
Discussion
In this 16-year study of 121 patients with PCP, we compared
the clinical characteristics of patients with and without HIV
infection. Previous studies were smaller [13–16] and were per-
formed in the era before the availability of antiretroviral ther-
apy and the introduction of primary PCP prophylaxis for HIV-
infected patients [14–16]. In our study, the main differences in
the presentation of PCP between HIV-positive and HIV-neg-
ative patients were as follows: HIV-positive patients were (1)
younger than HIV-negative patients, (2) had a longer duration
of symptoms, (3) a higher frequency of general symptoms
(sweating, weight loss, cachexia), and (4) a higher frequency of
thoracic pain. In addition, HIV-infected patients with PCP had
higher hemoglobin values, lower thrombocyte counts, and
lower C-reactive protein values. Hospital mortality was similar
in both groups. However, a greater proportion of HIV-negative
patients was treated in the ICU and mechanically ventilated.
In 3 published studies, the duration of symptoms in HIV-
infected patients was consistently longer than for HIV-negative
patients [13–15]. Mortality, however, was higher [15], lower [13],
or equal at a high level [14].
The higher proportion of HIV-negative patients admitted to
the ICU and requiring mechanical ventilation, as well as the
somewhat higher overall mortality, suggests that HIV-negative
patients with PCP had a higher rate of comorbidity than did
HIV-infected patients. The younger age of patients with AIDS
may also have contributed to their lesser need for an ICU stay
and mechanical ventilation. A third explanation is the higher
degree of suspicion of a diagnosis of PCP for HIV-infected
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Table 4. Length of hospital stay (LOS), intensive care unit (ICU)
data, and outcome for HIV-positive and HIV-negative patients.
Parameter
HIV-positive
(n = 89)
HIV-negative
(n = 32) P
LOS, mean no. of days (range)
1983–1998 20.5 (2–88) 22 (5–122) .31a
1983–1995 19.5 (2–88) 34 (5–122) !.01a
1996–1998 14.5 (2–50) 16 (4–69) .95a
In ICU
Patients 14 (16) 11 (31) !.05b
Mean no. of days (range) 6.5 (1–18) 13 (2–58) .65a
Mechanical ventilation 8 (16) 7 (64) !.05b
Deaths 3 (38) 4 (50) .3b
Deaths in hospital 10 (11) 5 (19) .54b
NOTE. Data are no. (%) of patients, except as noted.
a Mann-Whitney U test.
b Fisher’s exact test.
Figure 2. Mortality among patients admitted with Pneumocystis
carinii pnuemonia (PCP). White and black columns represent HIV-
positive and HIV-negative patients, respectively. There was trend to-
ward higher hospital mortality among HIV-negative patients until 1996
( , Fisher’s exact test).P = .13
patients, resulting in diagnosis and antimicrobial therapy at a
less advanced stage of pneumonia.
Indeed, despite a constant incidence of PCP of 10–14 cases
a year since 1990, the number of BALs performed at our hos-
pital for the diagnosis of PCP in HIV-infected patients increased
from 55 in 1990 to 79 in 1995. This suggests increasing aware-
ness of PCP on the part of emergency department physicians.
Compared to data for the period of 1983–1995, PCP-associated
mortality in HIV-negative patients, as well as the length of
hospital stay, sharply decreased to reach those for HIV-infected
patients (table 4; figure 2).
In contrast, mortality and length of hospital stay for HIV-
infected patients did not significantly change over time, nor did
the yearly number of transplantations increase. This suggests
that the focus on HIV infection, in association with increasing
experience in the treatment of opportunistic infections, has im-
proved the management of PCP in patients with other types of
immunosuppression.
Eosinophilia and lymphocytosis in the BAL specimens from
HIV-infected patients with PCP have been described elsewhere
[25]. These findings were absent in the group of immunosup-
pressed HIV-negative patients, probably because of their im-
munosuppressive therapy with corticosteroids.
PCP prophylaxis is well established for HIV-infected patients
and has proved to be effective [17–20]. Of the HIV-infected
patients who developed PCP, only 11% were receiving prophy-
laxis. This is in contrast to the overall data from the Swiss HIV
Cohort participants; 185% of them, for whom at least 2 CD4
cell counts were !200/mL, received PCP prophylaxis (personal
communication, Dr. M. Rickenbach, Swiss HIV Cohort Study
Data Center, Lausanne, Switzerland). This indicates that failure
of prophylaxis is rather infrequent, and PCP occurred mainly
in HIV-infected individuals at risk who did not receive PCP
prophylaxis.
The introduction of HAART in Switzerland has led to a
significant reduction in progression to AIDS in HIV-infected
patients [21]. This has led in turn to a marked decrease of
admissions for PCP in our hospital since 1995. In our study,
only 1 patient admitted for PCP was receiving HAART.
PCP prophylaxis has also proved to be effective in various
groups of HIV-negative immunosuppressed patients [26–29].
None of the HIV-negative patients included in this study was
receiving prophylaxis. Since PCP-related mortality is still high,
further efforts are needed to assess HIV-negative immunocom-
promised patients who may benefit from PCP prophylaxis. In
a recent observational study, it was suggested that PCP pro-
phylaxis should be given to all solid organ transplant recipients
for at least 1 year. In patients with recurrent or chronic rejection
and in lung transplant recipients, it should be continued during
risk and indefinitely, respectively [30]. In another observational
study on heart transplant recipients, PCP recurrence was not
observed when the CD4 cell count was 1150/mL [31].
In conclusion, HIV-infected patients with PCP differ in sev-
eral clinical and laboratory aspects from those with PCP but
without HIV infection. If PCP prophylaxis were used not only
for HIV-infected patients at risk but also for transplant patients
with absolute lymphocyte counts !500/mL and within 180 days
after transplantation, the incidence of PCP would probably
markedly drop.
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